COMPASS Pathways (CMPS)
| Bid | 4.54 |
| Market Cap | 310.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -2.08 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.79 |
| Volume | 763,924 |
| Avg. Volume (20D) | 1,020,174 |
| Open | 4.50 |
| Previous Close | 4.50 |
| Day's Range | 4.26 - 4.55 |
| 52-Week Range | 3.17 - 12.75 |
| Beta | undefined |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu...
Analyst Forecast
According to 6 analyst ratings, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 560.07% from the latest price.
1 month ago · businesswire.com
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient OfficerLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental ...
2 months ago · businesswire.com
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...
2 months ago · businesswire.com
Compass Pathways to Participate in December Investor ConferencesLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...